Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2026)
Aquestive Therapeutics (AQST) posted quarterly Return on Capital Employed of 46.96% for Q1 2026, up 234.0% year-over-year from 14.06% in Q1 2025, and up 24.4% quarter-over-quarter from 62.12% in Q4 2025.
Aquestive Therapeutics (AQST) Return on Capital Employed (2018 - 2026) Analysis & Trends
Aquestive Therapeutics' Return on Capital Employed history runs 9 years deep, the most recent figure standing at 46.96% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 234.0% year-over-year to 46.96%; the TTM figure through Mar 2026 stood at 46.96% (up 234.0% YoY), while the FY2025 annual figure was 85.28%, down 3446.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 46.96%, up from 62.12% in the prior quarter.
- The five-year high for Return on Capital Employed was 13.85% in Q2 2024, with the low at 281.76% in Q4 2022.
- The 5-year median for Return on Capital Employed is 62.12% (2025), against an average of 94.3%.
- The sharpest annual moves came in 2022 and 2023: Return on Capital Employed plunged 19856 bps in 2022, then soared 24413 bps in 2023.
- Aquestive Therapeutics' Return on Capital Employed stood at 281.76% in 2022, then jumped by 87 bps to 37.64% in 2023, then rose by 6 bps to 35.44% in 2024, then slumped by 75 bps to 62.12% in 2025, then climbed by 24 bps to 46.96% in 2026.
- Business Quant data shows AQST's Return on Capital Employed at 46.96% in Q1 2026, 62.12% in Q4 2025, and 54.14% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Aquestive Therapeutics | 554.35 Mn | 554.35 Mn | 9.80 Mn | -43.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -43.90% |
| Mar 31, 2026 | -46.96% |
| Dec 31, 2025 | -62.12% |
| Sep 30, 2025 | -54.14% |
| Jun 30, 2025 | -70.31% |
| Mar 31, 2025 | -49.30% |
| Dec 31, 2024 | -35.44% |
| Sep 30, 2024 | -21.40% |
| Jun 30, 2024 | -13.85% |
| Mar 31, 2024 | -25.80% |
| Dec 31, 2023 | -37.64% |
| Sep 30, 2023 | -64.11% |
| Jun 30, 2023 | -138.53% |
| Mar 31, 2023 | -196.51% |
| Dec 31, 2022 | -281.76% |
| Sep 30, 2022 | -245.59% |
| Jun 30, 2022 | -157.32% |
| Mar 31, 2022 | -102.32% |
| Dec 31, 2021 | -83.20% |
| Sep 30, 2021 | -94.18% |